BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10799812)

  • 1. Characterization of the physicochemical properties of the micelles by the novel platelet activating factor receptor antagonist E5880.
    Asai Y; Watanabe S
    Eur J Pharm Biopharm; 2000 May; 49(3):219-23. PubMed ID: 10799812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880.
    Asai Y
    Pharm Dev Technol; 2005; 10(1):11-6. PubMed ID: 15776809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of the formulation and characterization of the physicochemical properties of the novel platelet-activating factor receptor antagonist E5880.
    Asai Y; Murahashi N; Iwamoto K
    Drug Dev Ind Pharm; 2000 Aug; 26(8):873-8. PubMed ID: 10900544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of spherical micelles by the novel platelet activating factor receptor antagonist, E5880.
    Nomura T; Asai Y; Murahashi N; Iwamoto K
    Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):947-50. PubMed ID: 10923821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880.
    Asai Y
    Pharmazie; 2005 Mar; 60(3):201-4. PubMed ID: 15801673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the physicochemical properties of micelles composed of the novel platelet activating factor receptor antagonist, E5880 in an aqueous environment.
    Asai Y
    Chem Phys Lipids; 2003 Jul; 124(2):103-9. PubMed ID: 12818736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880.
    Suzuki H; Asano O; Tadano K; Horie T
    J Pharm Sci; 1994 May; 83(5):657-61. PubMed ID: 8071816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A temperature study on critical micellization concentration of the novel platelet-activating factor receptor antagonist E5880 in water by electric conductivity measurements.
    Asai Y; Nomura T; Murahashi N; Iwamoto K
    Drug Dev Ind Pharm; 2000 May; 26(5):555-8. PubMed ID: 10789068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety.
    Hirashima Y; Endo S; Nukui H; Kobayashi N; Takaku A
    Neurol Med Chir (Tokyo); 2001 Apr; 41(4):165-75; discussion 175-6. PubMed ID: 11381675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-299, a potent antagonist of platelet activating factor.
    Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of a platelet-activating factor antagonist, E5880, on cerebrovasospasm following subarachnoid hemorrhage in a canine double-hemorrhage model.
    Abe Y; Kasuya H; Suzuki S; Yamanishi Y; Hori T
    Eur J Pharmacol; 2002 Nov; 455(2-3):127-33. PubMed ID: 12445578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor.
    Brewer C; Bonin F; Bullock P; Nault MC; Morin J; Imbeault S; Shen TY; Franks DJ; Bennett SA
    J Neurochem; 2002 Sep; 82(6):1502-11. PubMed ID: 12354298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor antagonists.
    Koltai M; Braquet PG
    Clin Rev Allergy; 1994; 12(4):361-80. PubMed ID: 7743462
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of the physicochemical properties of the micelles of platelet-activating factor (C18:0).
    Asai Y; Nomura T; Murahashi N; Iwamoto K
    Drug Dev Ind Pharm; 2000 Jun; 26(6):671-4. PubMed ID: 10826115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of platelet-activating factor antagonist E5880 on intrahepatic and systemic metabolic responses to transient hepatic inflow occlusion and reperfusion in the rabbit.
    Nakatani T; Sakamoto Y; Ando H; Kobayashi K
    World J Surg; 1996 Oct; 20(8):1060-7; discussion 1067-8. PubMed ID: 8798365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis.
    Curtis LD
    Adv Exp Med Biol; 1996; 416():361-3. PubMed ID: 9131174
    [No Abstract]   [Full Text] [Related]  

  • 18. Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
    Elder CA; Modi MW
    Drug Metab Dispos; 1995 Jul; 23(7):776-8. PubMed ID: 7587967
    [No Abstract]   [Full Text] [Related]  

  • 19. Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists.
    Houlihan WJ; Cheon SH; Parrino VA; Handley DA; Larson DA
    J Med Chem; 1993 Oct; 36(21):3098-102. PubMed ID: 8230095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists.
    Handley DA
    Med Res Rev; 1990; 10(3):351-70. PubMed ID: 2164623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.